Intravenous (i.v.)temsirolimus, a novel inhibitor of mammalian target of rapamycin, is approved for the treatment of advanced renal cell carcinoma and is being studied in patients with mantle cell lymphoma. The gene discussed is MTOR; the disease is hereditary clear cell renal cell carcinoma.